Traws Pharma, Inc. quarterly report, Q2 FY2018

Filing and business context

This is Onconova Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018. The request identifies Traws Pharma, Inc.; the filing itself names Onconova, so the company identity should be verified. Onconova is a clinical-stage oncology biopharmaceutical company, with most current effort focused on rigosertib.

Financial results and liquidity

At June 30, cash and cash equivalents were $29.540 million, working capital was $20.2 million, total assets were $30.203 million, and total liabilities were $14.288 million. The company reported no interest-bearing debt; the balance sheet includes a $448,000 warrant liability. No gross margin is presented. Cash increased by $25.516 million during the first half, mainly reflecting $35.657 million of financing proceeds, including the February and May equity-and-warrant offerings. The company estimates cash will fund ongoing trials and operations into the fourth quarter of 2019, but states there is substantial doubt about its ability to continue as a going concern without additional funding.

Changes versus the prior comparable period

• Second-quarter revenue rose 50% to $485,000 from $324,000, primarily due to Pint license revenue, partly offset by lower SymBio clinical-supply revenue. First-half revenue increased to $1.049 million from $534,000, including revenue recognized from HanX and Pint.
• Second-quarter operating expenses declined to $6.124 million from $6.393 million; R&D fell 12% to $4.070 million, while G&A rose 15% to $2.054 million. For the first half, operating expenses fell to $12.590 million from $13.395 million, mainly due to lower R&D costs.
• Second-quarter consolidated net loss widened to $4.321 million from $2.584 million, despite improved operating loss. The comparison reflects a smaller favorable warrant revaluation ($513,000 versus $3.474 million); the 2018 quarter also included a $693,000 gain on dissolution of GBO. First-half consolidated net loss narrowed to $9.411 million from $10.925 million.
• Operating cash use improved to $10.133 million in the first half from $11.749 million in the prior-year period. Equity increased from a $10.861 million deficit at year-end 2017 to $15.915 million at June 30, 2018, primarily reflecting offerings, partly offset by losses.

Outlook, developments, and risks

• The Phase 3 INSPIRE trial of intravenous rigosertib continues after an interim review. The independent monitoring committee recommended a pre-planned enrollment expansion from 225 to 360 patients, with the targeted death events increased from 176 to 288. The company remained blinded to interim results and expected trial completion in the second half of 2019.
• The company says it will not commence the planned Phase 3 trial of oral rigosertib with azacitidine for higher-risk MDS, or further development of oral rigosertib for lower-risk MDS or AML, without additional financing. It also reports ongoing development work on other candidates and an NCI collaboration for rigosertib research in pediatric RASopathies.
• Onconova received $25.6 million net from its May offering and $8.7 million from its February offering. These transactions substantially increased shares and included pre-funded and preferred-stock warrants, creating significant potential dilution. The common-stock authorization was increased to 250 million shares. Stockholders authorized a possible 1-for-5 to 1-for-15 reverse split; the board had not selected a ratio or effective date as of the filing.
• Nasdaq notified the company that it did not meet the $1 minimum bid-price requirement. The stated compliance deadline was November 5, 2018, with a possible additional compliance period subject to conditions; delisting could impair liquidity and fundraising.
• The filing identifies continuing financing and going-concern risks, clinical and regulatory uncertainty, reliance on collaborations and third parties, and potential dilution or unfavorable financing terms. It reports no pending material legal proceedings. Management said disclosure controls were effective and that no material change in internal control over financial reporting occurred during the quarter.

Important facts for investors to verify

• Confirm that this Onconova filing—not a Traws Pharma filing—is the intended document.
• Track actual cash burn, financing needs, and whether the stated cash runway remains achievable; management explicitly cites substantial going-concern doubt.
• Monitor INSPIRE enrollment, trial timing, and eventual overall-survival results, noting that interim results were blinded.
• Assess the fully diluted share count and terms/exercise of warrants and preferred securities, including dilution from the 2018 offerings.
• Check Nasdaq bid-price compliance, any reverse-split action, and the resulting listing status.